Physician profile
Upinder K Basi
NPI 1891782009
$1,760.64
in general payments reported to CMS, 2019-2025
20 companies · $114 in 2025
The $114 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $324 · 2022: $31.97 · 2023: $0.79 · 2024: $119 · 2025: $114.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.41 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $267.09 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $232.89 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $208.66 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $201.45 | 2019-2024 | Farxiga |
| Novo Nordisk INC | $161.92 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $159.55 | 2019-2020 | |
| Astellas Pharma US INC | $106.69 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $53.31 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $49.70 | 2019 | |
| Abbott Laboratories | $49.07 | 2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $48.64 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $40.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $39.74 | 2019 | |
| Abbvie INC. | $31.97 | 2022 | |
| Sanofi-Aventis U.S. LLC | $28.15 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $25.45 | 2020 | |
| Allergan, INC. | $23.32 | 2020 | |
| Lilly USA, LLC | $18.01 | 2020 | |
| Philips North America LLC | $13.45 | 2020 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Upinder Basi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.